Xtant Medical Q4 GAAP EPS $(0.03) Misses $(0.02) Estimate, Sales $28.11M Beat $26.55M Estimate
Portfolio Pulse from Benzinga Newsdesk
Xtant Medical Holdings (AMEX:XTNT) reported Q4 GAAP EPS of $(0.03), missing the $(0.02) estimate, but sales of $28.11M exceeded the $26.55M estimate, marking an 84.07% increase from last year.
April 01, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Xtant Medical reported a Q4 GAAP EPS of $(0.03), missing estimates by 50%, but sales of $28.11M exceeded expectations, showing a significant year-over-year growth of 84.07%.
While the EPS miss might concern some investors, the significant sales beat and year-over-year growth could offset negative sentiment. The mixed results present a neutral short-term outlook for XTNT's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100